LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Genialis, the RNA-biomarker company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, have reached an agreement to define and discover biomarkers within the DNA Damage Repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.

瑞士洛桑和波士顿——（商业新闻短讯）——RNA生物标志物公司Genialis和瑞士私营生物制药公司Debiopharm，旨在建立未来治疗癌症和传染病的护理标准，已经达成协议，在DNA损伤修复（DDR）生物学空间中定义和发现生物标志物，以预测Debiopharm管道中一种或多种药物的临床益处。

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderID framework to develop predictive biomarkers for DDR-directed therapies..

最初的阶段于本月开始，首先部署了Genialis的生物学，机器学习支持的ResponderID框架，以开发用于DDR指导疗法的预测性生物标志物。。

“Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs. Genialis’ expertise and cutting-edge technologies are an ideal fit to help us make the smartest translational decisions and advance our drugs to reach the right patients,” said Bertrand Ducrey, CEO of Debiopharm..

Debiopharm首席执行官Bertrand Ducrey表示：“Debiopharm在临床前和临床开发项目的各个阶段都在采用人工智能解决方案，在肿瘤学领域继续处于领先地位。Genialis的专业知识和尖端技术非常适合帮助我们做出最明智的转化决策，并推动我们的药物到达正确的患者。”。。

Many cancers exhibit deficiencies in one or more DNA damage response pathways. Various classes of approved and investigational drugs aim to exploit known sensitivities; however, the heterogeneous biology of DNA damage response means that one drug only fits some, and combinations may prove essential.

许多癌症在一种或多种DNA损伤反应途径中表现出缺陷。各类批准和研究药物旨在利用已知的敏感性；然而，DNA损伤反应的异质生物学意味着一种药物只适合某些药物，并且组合可能被证明是必不可少的。

Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism..

生物标志物将有助于选择癌症生物学最适合使用针对活动性疾病机制的正确药物治疗的患者。。

“DNA damage response is among the most exciting biological domains of cancer drug development today and an area in which Debiopharm is working on several exciting molecules,” said Carolina Haefliger, Head of Translational Medicine at Debiopharm. “Genialis’ biology-first approach allows us to collaborate in a truly scalable way, incorporating novel AI-based solutions in our programs.”.

Debiopharm转化医学负责人Carolina Haefliger说：“DNA损伤反应是当今癌症药物开发中最令人兴奋的生物学领域之一，也是Debiopharm正在研究几种令人兴奋的分子的领域。”。“Genialis的生物学优先方法使我们能够以真正可扩展的方式进行合作，将新颖的基于人工智能的解决方案纳入我们的程序。”。

Using biomarkers increases the odds of advancing an oncology clinical asset to the next trial phase by 5-12 fold1. However, post-approval, many of the best drugs achieve clinical benefit in only 30-40 percent of patients, and even those existing targeted therapies considered successful and supported by a biomarker can benefit from further refinement of patient tailoring strategies..

使用生物标志物可将肿瘤学临床资产推进下一个试验阶段的几率提高5-12倍1。然而，在批准后，许多最好的药物仅在30-40%的患者中获得临床益处，即使是那些被认为成功并得到生物标志物支持的现有靶向治疗也可以从患者定制策略的进一步改进中受益。。

“Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis. “Debiopharm is working on some really promising molecules, and Genialis' biomarkers will help ensure these drugs have the best possible chance of clinical success.”.

Genialis生物标志物发现副总裁Mark Uhlik说：“Genialis的RNA生物标志物已被证明特别适合支持针对复杂生物系统的新药开发。”。“Debiopharm正在研究一些真正有前途的分子，Genialis的生物标志物将有助于确保这些药物获得临床成功的最佳机会。”。

Genialis is based in Boston, Mass., and will attend PMWC in Santa Clara, Calif., from January 23-25, 2024. To request a meeting or for more information on ResponderID, please email biomarkers@genialis.com or visit www.genialis.com.

Genialis总部位于马萨诸塞州波士顿，将于2024年1月23日至25日在加利福尼亚州圣克拉拉参加PMWC。要请求会议或了解ResponderID的更多信息，请发送电子邮件biomarkers@genialis.com或访问www.genialis.com。

Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.

Debiopharm总部位于瑞士洛桑，将于2024年1月29日至30日在波士顿举行的第七届DDR抑制年度会议上发表演讲。

About DNA-Damage Repair (DDR)

关于DNA损伤修复（DDR）

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells use their hyperactive DDR response to divide and grow uncontrollably, which promotes cancer expansion. Inhibition of DDR, particularly in combination with other anticancer agents, induces an overall arrest in the uncontrollable cancer cell cycle.

当细胞DNA受损时，它们需要经历一个称为DDR的修复过程才能存活。癌细胞利用其过度活跃的DDR反应不受控制地分裂和生长，从而促进癌症的扩散。抑制DDR，特别是与其他抗癌剂联合使用，可诱导不可控制的癌细胞周期全面停滞。

This ultimately activates a self-destruction program in cancer cells. DDR inhibitors are currently being tested in preclinical and clinical studies..

这最终激活了癌细胞的自我毁灭程序。DDR抑制剂目前正在临床前和临床研究中进行测试。。

About Genialis

关于Genialis

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. ResponderID™, Genialis’ machine-learning-driven disease modeling framework, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development and ensure the best possible clinical care.

RNA生物标志物公司Genialis正在创造一个世界，在这个世界上，医疗保健为患者及其家人和社区提供尽可能最好的结果。响应者ID™, Genialis的机器学习驱动的疾病建模框架，提供了可行的生物标志物，并对新药进行了最佳定位，以加速转化研究，简化药物开发并确保最佳的临床护理。

Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit www.genialis.com..

Genialis受到制药和诊断合作伙伴的信任，我们正通过数据共同改变医学。有关更多信息，请访问www.genialis.com。。

About Debiopharm

关于Debiopharm

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.

Debiopharm是一家总部位于瑞士的独立生物制药公司，致力于制定未来的治疗癌症和传染病的标准，并提高患者的生活质量。Debiopharm的主要活动包括药物开发、药物制造和数字健康投资。

The company believes in the future digital biology where AI is the main engine for this transformation. For more information, please visit www.debiopharm.com..

该公司相信未来的数字生物学，人工智能是这种转变的主要引擎。有关更多信息，请访问www.debiopharm.com。。

_______________________

_______________________

1Parker JL et al, 2021: doi:10.1002/cam4.3732

1Parker JL等人，2021:doi:10.1002/cam4.3732